PD
MLYS icon

Point72 (DIFC)’s Mineralys Therapeutics MLYS Stock Holding History

Point72 (DIFC)’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$153K Buy
+4,037
New +$87.3K 0.01% 500

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 (DIFC)'s MLYS Position: Q3 2025 in Review

Point72 (DIFC) opened a new position in Mineralys Therapeutics (MLYS) in Q3 2025: 4,037 shares worth $153K. The stake represents 0.01% of the portfolio and ranks #500 among its holdings.

193 funds tracked by Wall St. Rank hold MLYS as of Q3 2025.

  • Point72 (DIFC) held 4,037 shares of Mineralys Therapeutics worth $153K as of Q3 2025.
  • Mineralys Therapeutics was a new Point72 (DIFC) position in Q3 2025.
  • Mineralys Therapeutics made up 0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #500 holding.
  • 193 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.